Supernus to Present at the Jefferies 2019 Global Healthcare Conference
May 29 2019 - 4:15PM
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases, today announced that
the Company's management will present a Company overview and
update, as well as host investor meetings, at the Jefferies 2019
Global Healthcare Conference.
Date: Wednesday, June 5, 2019Time: 2:00 p.m. ET Place: Grand
Hyatt New York in New York City
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
A live webcast of the presentation can be accessed by visiting
‘Events & Presentations’ in the Investors section on the
Company's website at www.supernus.com. An archived replay of the
webcast will be available for 60 days on the Company's website
after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company
focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases. The Company
currently markets Trokendi XR® (extended-release topiramate) for
the prophylaxis of migraine and the treatment of epilepsy, and
Oxtellar XR® (extended-release oxcarbazepine) for the treatment of
epilepsy. The Company is also developing several product candidates
to address large market opportunities in the CNS market, including
SPN-810 for the treatment of Impulsive Aggression in ADHD patients,
SPN-812 for the treatment of ADHD, and SPN-604 for the treatment of
bipolar disorder.
Contact:
Jack A. Khattar, President and CEOGregory S. Patrick, Senior
Vice President and CFOSupernus Pharmaceuticals,
Inc.301-838-2591
Or
Investor Contact:Peter VozzoWestwicke PartnersOffice: (443)
213-0505Mobile: (443) 377-4767Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024